Fig. 3: Circulating GH, IGF1, ALS and IGFBP3 of AAV8-HLP-mGHR treated Laron mice.
From: First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model
Serum level of mouse (a) GH, (b) IGF1, (c) ALS, (d) IGFBP3 and (e) IGF1:IGFBP3 molar ratio at end point in (i) male and (ii) female of uninjected GHR+/+, GHR+/−, GHR−/− and AAV-injected Laron dwarf mice with AAV8-HLP-Luc and AAV8-HLP-mGHR. Data were presented as mean ± s.e.m. n = 3–6. Statistical significances were determined by Student’s unpaired t-test where ns indicated not significant, * indicates p < 0.05 and considered statistically significant, ** indicates p < 0.01 and considered very significant, *** indicates p < 0.001 and considered extremely significant and **** indicates p < 0.0001 and considered extremely significant.
